Biotech 2050 Podcast

Curran Simpson, President & CEO of REGENXBIO, on Gene Therapy, Strategy & Patient-Centered Impact


Listen Later

Synopsis:
When an introverted engineer becomes the President & CEO of REGENXBIO, transformation follows. Curran Simpson joins host Rahul Chaturvedi to unpack his unlikely journey from biotech operations to the C-suite—and how that hands-on experience is reshaping gene therapy's future.
They dive into the evolution of REGENXBIO’s pipeline, tackling ultra-rare diseases like MPS II, ambitious plans for Duchenne Muscular Dystrophy, and commercial partnerships with giants like AbbVie. Curran offers hard-earned leadership lessons, honest reflections on scaling science, and insights into how one-time gene therapies could revolutionize treatment in both rare and common diseases.
From clinical nuance to strategic boldness, this is a masterclass in biotech leadership, platform focus, and staying patient-first—no matter how complex the science or market.
Biography:
Curran M. Simpson is the President and Chief Executive Officer and member of the Board of Directors at REGENXBIO. Mr. Simpson previously served as the Company’s Chief Operating Officer. In that role, he led key business functions including Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations. Mr. Simpson joined REGENXBIO in 2015 with extensive leadership experience across biopharmaceutical operations and served as the Company’s Chief Technology and Operations Officer before becoming COO. Prior to joining REGENXBIO, he was the Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline (GSK). Mr. Simpson earlier served as interim CEO of Human Genome Sciences (HGS), where he led the integration of HGS into GSK, and as Senior Vice President of Operations and Vice President of Manufacturing Operations at HGS. Prior to HGS, Mr. Simpson was Director of Manufacturing Sciences at Biogen. Earlier in his career, Mr. Simpson served in an overseas assignment at Novo-Nordisk Biochem in Denmark and in various senior development and engineer roles at Genentech, working on Herceptin and Avastin, among other roles. Mr. Simpson has an M.S. in surface and colloid science from Clarkson University and a B.S. in chemistry from the Clarkson College of Technology.
...more
View all episodesView all episodes
Download on the App Store

Biotech 2050 PodcastBy Biotech 2050

  • 4.7
  • 4.7
  • 4.7
  • 4.7
  • 4.7

4.7

59 ratings


More shows like Biotech 2050 Podcast

View all
WSJ Your Money Briefing by The Wall Street Journal

WSJ Your Money Briefing

1,713 Listeners

Exchanges by Goldman Sachs

Exchanges

975 Listeners

The Knowledge Project with Shane Parrish by Shane Parrish

The Knowledge Project with Shane Parrish

2,665 Listeners

Odd Lots by Bloomberg

Odd Lots

1,905 Listeners

Masters of Scale by WaitWhat

Masters of Scale

3,993 Listeners

The Long Run with Luke Timmerman by Timmerman Report

The Long Run with Luke Timmerman

122 Listeners

The Readout Loud by STAT

The Readout Loud

317 Listeners

The Intrinsic Value Podcast - The Investor’s Podcast Network by The Investor's Podcast Network

The Intrinsic Value Podcast - The Investor’s Podcast Network

559 Listeners

Business Of Biotech by Ben Comer

Business Of Biotech

86 Listeners

BioCentury This Week by BioCentury

BioCentury This Week

30 Listeners

Raising Health by Andreessen Horowitz, a16z Bio + Health

Raising Health

144 Listeners

Business Breakdowns by Colossus | Investing & Business Podcasts

Business Breakdowns

344 Listeners

Biotech Hangout by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more

Biotech Hangout

17 Listeners

The So What from BCG by Boston Consulting Group BCG

The So What from BCG

221 Listeners

HBR On Leadership by Harvard Business Review

HBR On Leadership

163 Listeners